The Hempshire Group, Inc. (HMPSF) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
$'dan işlem gören The Hempshire Group, Inc. (HMPSF), 0 değerindeki bir Healthcare şirketidir. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 41/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 17 Mar 2026The Hempshire Group, Inc. (HMPSF) Sağlık ve Boru Hattı Genel Bakışı
The Hempshire Group, Inc., established in 2019, focuses on the pharmaceutical-grade hemp and CBD product sector. Operating with a small team, the company engages in sourcing, manufacturing, and branding, distinguishing itself in the competitive specialty and generic drug manufacturing industry through its focus on hemp-derived products.
Yatırım Tezi
The Hempshire Group, Inc. presents a high-risk, high-reward investment profile. The company's negative P/E ratio of -1.97 and a profit margin of -7300.9% indicate significant challenges in achieving profitability. However, its gross margin of 28.8% suggests potential in its core operations if costs can be managed effectively. A beta of 0.12 indicates low volatility compared to the market. Growth catalysts include potential expansion of its product line and increased market penetration in the growing CBD sector. The company's small size and limited resources pose risks, but successful execution of its business plan could lead to substantial returns. Investors should carefully consider the company's financial position and competitive landscape before investing.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market capitalization of $0.02 billion, indicating a micro-cap company.
- Negative P/E ratio of -1.97, reflecting current losses.
- Profit margin of -7300.9%, highlighting significant operational inefficiencies.
- Gross margin of 28.8%, suggesting potential for profitability with improved cost management.
- Beta of 0.12, indicating lower volatility compared to the overall market.
Rakipler & Benzerleri
Güçlü Yönler
- Focus on pharmaceutical-grade hemp and CBD products.
- Established brand in a growing market.
- Proprietary processing techniques.
- Experienced management team.
Zayıflıklar
- Small size and limited resources.
- Negative profitability and high losses.
- Reliance on a niche market.
- Limited distribution network.
Katalizörler
- Upcoming: Potential regulatory changes in the CBD market could create new opportunities for Hempshire.
- Ongoing: Expansion of product line to include new CBD-infused products.
- Ongoing: Strategic partnerships with established pharmaceutical companies or retailers.
Riskler
- Potential: Intense competition in the CBD market could erode market share.
- Potential: Regulatory uncertainty and changing laws could negatively impact operations.
- Ongoing: Fluctuations in hemp prices could affect profitability.
- Ongoing: Limited financial resources may hinder growth initiatives.
- Potential: Negative P/E ratio and profit margin indicate financial instability.
Büyüme Fırsatları
- Expansion of Product Line: Hempshire can expand its product line to include a wider range of CBD-infused products, such as topicals, edibles, and beverages. The global CBD market is projected to reach $55.79 billion by 2028, offering significant growth potential. By diversifying its offerings, Hempshire can attract a broader customer base and increase revenue streams. Successful product development and marketing will be crucial for capturing market share.
- Strategic Partnerships: Forming strategic partnerships with established pharmaceutical companies or retailers could provide Hempshire with access to wider distribution networks and increased brand visibility. Collaborations can also facilitate research and development efforts, leading to innovative product formulations. The timeline for establishing such partnerships is dependent on negotiation and due diligence processes, but could yield significant benefits within the next 1-2 years.
- International Expansion: Exploring opportunities to expand into international markets, particularly in Europe and Asia, where the demand for CBD products is growing, represents a significant growth driver. Navigating regulatory requirements and establishing distribution channels in new markets will be essential for successful international expansion. This initiative could take 2-3 years to fully implement, but offers long-term growth potential.
- Focus on Research and Development: Investing in research and development to create novel CBD formulations and delivery methods can provide Hempshire with a competitive advantage. Developing proprietary technologies and intellectual property can also attract investment and partnership opportunities. The timeline for R&D initiatives can vary depending on the complexity of the projects, but could yield significant results within 3-5 years.
- Direct-to-Consumer Sales: Establishing a strong online presence and direct-to-consumer sales channel can improve margins and provide greater control over the customer experience. Investing in e-commerce infrastructure and digital marketing can drive online sales and build brand loyalty. This initiative can be implemented relatively quickly, with noticeable results within the next 6-12 months.
Fırsatlar
- Expansion of product line.
- Strategic partnerships with larger companies.
- International market expansion.
- Increased research and development.
Tehditler
- Intense competition in the CBD market.
- Regulatory uncertainty and changing laws.
- Fluctuations in hemp prices.
- Economic downturn affecting consumer spending.
Rekabet Avantajları
- Focus on pharmaceutical-grade quality.
- Specialization in hemp and CBD products.
- Established branding and marketing strategies.
- Proprietary processing techniques.
HMPSF Hakkında
The Hempshire Group, Inc., founded in 2019 and based in Palm Springs, California, operates within the healthcare sector, specifically in the specialty and generic drug manufacturing industry. The company is involved in the sourcing, manufacturing, branding, and processing of pharmaceutical-grade hemp and CBD products. Hempshire's focus is on creating and distributing products derived from hemp, positioning itself in a niche market within the broader pharmaceutical landscape. The company's operations encompass the entire product lifecycle, from sourcing raw materials to manufacturing finished goods and establishing brand recognition. With a small team of 8 employees, Hempshire navigates the complexities of the pharmaceutical industry, targeting consumers seeking hemp and CBD-based health and wellness solutions. The company's strategic focus on pharmaceutical-grade products underscores a commitment to quality and regulatory compliance, differentiating it from other players in the hemp and CBD market.
Ne Yaparlar
- Sources pharmaceutical-grade hemp.
- Manufactures CBD products.
- Brands and markets its products.
- Processes hemp for various applications.
- Focuses on the healthcare sector.
- Operates in the specialty and generic drug manufacturing industry.
İş Modeli
- Sourcing high-quality hemp.
- Manufacturing CBD products.
- Branding and marketing for direct sales and distribution.
- Processing hemp for pharmaceutical applications.
Sektör Bağlamı
The Hempshire Group, Inc. operates in the specialty and generic drug manufacturing industry, which is experiencing growth driven by increasing demand for alternative medicines and wellness products. The CBD market, in particular, is expanding rapidly, but faces regulatory uncertainty and intense competition. Hempshire's focus on pharmaceutical-grade hemp and CBD products positions it within a niche segment that emphasizes quality and compliance. The company competes with both established pharmaceutical companies and smaller, specialized CBD manufacturers. Success in this market requires effective branding, distribution, and adherence to evolving regulatory standards.
Kilit Müşteriler
- Consumers seeking hemp-based wellness products.
- Patients looking for alternative treatments.
- Retailers and distributors of health and wellness products.
Finansallar
Grafik & Bilgi
The Hempshire Group, Inc. (HMPSF) hisse senedi fiyatı: Price data unavailable
Son Haberler
HMPSF için son haber bulunmamaktadır.
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
HMPSF için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
HMPSF için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, HMPSF'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Yönetim: Shawn Balaghi
CEO
Shawn Balaghi is the CEO of The Hempshire Group, Inc. His background includes experience in managing and developing businesses, with a focus on the healthcare and wellness sectors. He has been instrumental in guiding the company's strategic direction and overseeing its operations. Balaghi's leadership is focused on driving innovation and growth within the competitive CBD market.
Sicil: Under Shawn Balaghi's leadership, The Hempshire Group, Inc. has focused on establishing a presence in the pharmaceutical-grade hemp and CBD market. Key milestones include developing a range of CBD products and establishing partnerships with distributors. Balaghi's strategic decisions have aimed at positioning the company for long-term growth and success in the evolving CBD industry.
HMPSF OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the OTC market, indicating that The Hempshire Group, Inc. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited reporting requirements and may not be subject to the same level of scrutiny as those listed on major exchanges like the NYSE or NASDAQ. This tier is generally associated with higher risk and lower liquidity compared to listed exchanges.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited financial disclosure requirements.
- Lower liquidity and potential price volatility.
- Higher risk of fraud or mismanagement.
- Potential for delisting or trading suspension.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings.
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's compliance with regulatory requirements.
- Check for any legal or regulatory issues.
- Monitor trading volume and price activity.
- Consult with a financial advisor.
- Established business operations since 2019.
- Focus on pharmaceutical-grade products.
- Presence in the growing CBD market.
- Active engagement with investors and stakeholders.
HMPSF Healthcare Hisse Senedi SSS
HMPSF için değerlendirilmesi gereken temel faktörler nelerdir?
The Hempshire Group, Inc. (HMPSF) şu anda yapay zeka skoru 41/100, düşük puanı gösteriyor. Temel güçlü yan: Focus on pharmaceutical-grade hemp and CBD products.. İzlenmesi gereken birincil risk: Potential: Intense competition in the CBD market could erode market share.. Bu bir finansal tavsiye değildir.
HMPSF MoonshotScore'u nedir?
HMPSF şu anda MoonshotScore'da 41/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
HMPSF verileri ne sıklıkla güncellenir?
HMPSF fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler HMPSF hakkında ne diyor?
HMPSF için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
HMPSF'a yatırım yapmanın riskleri nelerdir?
HMPSF için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Intense competition in the CBD market could erode market share.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
HMPSF'ın P/E oranı nedir?
HMPSF için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için HMPSF'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
HMPSF aşırı değerli mi, yoksa düşük değerli mi?
The Hempshire Group, Inc. (HMPSF)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
HMPSF'ın temettü verimi nedir?
The Hempshire Group, Inc. (HMPSF) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Limited information available on OTC-listed companies.
- Financial data may not be fully up-to-date.